BioNTech Navigates Tumultuous Waters Amid Transition from Covid-19 Success to Cancer Research Aspirations
BioNTech, known for its Covid-19 vaccine, faces declining profits as it shifts focus to cancer research using mRNA technology. The company's earnings and revenue decreased significantly in 2024, though they…